“I am very encouraged that both clinicians and caregivers observed pervasiveimprovements across multiple, clinically important features of PMS…”
Like you Tin Shed Trader, I’m so happy for another group of patients that will benefit from this molecule eventually. In thinking about the much smaller number of GI issues in this trial, I’m hoping that Katelin and others like her, who are experiencing significant GI issues taking Daybue, may have the option to switch to NNZ-2591 in future if possible.
Raising a glass (again) today to Dame Margaret Brimble, along with Jon and the team and all fellow investors on this forum.
Ann: P2 trial shows significant improvements in Phelan-McDermid, page-46
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.26 |
Change
-0.280(2.23%) |
Mkt cap ! $1.525B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $6.952M | 570.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 231 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.32 | 1979 | 2 |
View Market Depth
| Last trade - 16.13pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |